{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484 254 6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 67, "title": "Co-Founder, Chief Scientist Officer, Chairman & Interim CEO", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 630198, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard Clavano Narido", "age": 46, "title": "Treasurer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 255015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael S. Abrams", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 62, "title": "Chief Manufacturing & Technology Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 77, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 61, "title": "Chief Business Officer & Co-CEO of Hope Therapeutics", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.05, "open": 2.06, "dayLow": 1.9034, "dayHigh": 2.1, "regularMarketPreviousClose": 2.05, "regularMarketOpen": 2.06, "regularMarketDayLow": 1.9034, "regularMarketDayHigh": 2.1, "payoutRatio": 0.0, "beta": 1.224, "forwardPE": -1.5275592, "volume": 162364, "regularMarketVolume": 162364, "averageVolume": 730936, "averageVolume10days": 181850, "averageDailyVolume10Day": 181850, "bid": 1.91, "ask": 1.98, "bidSize": 1, "askSize": 1, "marketCap": 32816264, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 6.01, "fiftyDayAverage": 2.5148, "twoHundredDayAverage": 2.084145, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 37630356, "profitMargins": 0.0, "floatShares": 14025947, "sharesOutstanding": 16915600, "sharesShort": 1025086, "sharesShortPriorMonth": 1151255, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.060599998, "heldPercentInsiders": 0.17083, "heldPercentInstitutions": 0.062, "shortRatio": 4.63, "shortPercentOfFloat": 0.0681, "impliedSharesOutstanding": 17420600, "bookValue": -1.592, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -25126000, "trailingEps": -2.36, "forwardEps": -1.27, "lastSplitFactor": "1:10", "lastSplitDate": 1712016000, "enterpriseToEbitda": -1.91, "52WeekChange": -0.5907173, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 1.94, "targetHighPrice": 45.0, "targetLowPrice": 19.0, "targetMeanPrice": 31.66667, "targetMedianPrice": 31.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 1443000, "totalCashPerShare": 0.085, "ebitda": -19699000, "totalDebt": 6257000, "quickRatio": 0.066, "currentRatio": 0.151, "returnOnAssets": -2.2460299, "freeCashflow": 126250, "operatingCashflow": -10637000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "NRXP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "NRX Pharmaceuticals, Inc.", "corporateActions": [], "preMarketTime": 1743595202, "regularMarketTime": 1743537600, "exchange": "NCM", "messageBoardId": "finmb_319388181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChange": -0.5748, "fiftyDayAverageChangePercent": -0.22856688, "twoHundredDayAverageChange": -0.14414501, "twoHundredDayAverageChangePercent": -0.06916266, "priceToBook": -1.218593, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroRx, Inc.", "nameChangeDate": "2025-04-01", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "marketState": "PRE", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1512397800000, "preMarketChange": 0.029899955, "preMarketChangePercent": 1.5412347, "preMarketPrice": 1.9699, "regularMarketChange": -0.109999895, "regularMarketDayRange": "1.9034 - 2.1", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 730936, "fiftyTwoWeekLowChange": 0.84000003, "fiftyTwoWeekLowChangePercent": 0.76363635, "fiftyTwoWeekRange": "1.1 - 6.01", "fiftyTwoWeekHighChange": -4.07, "fiftyTwoWeekHighChangePercent": -0.67720467, "fiftyTwoWeekChangePercent": -59.07173, "earningsTimestamp": 1742212922, "earningsTimestampStart": 1747047540, "earningsTimestampEnd": 1747396800, "earningsCallTimestampStart": 1742214600, "earningsCallTimestampEnd": 1742214600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.36, "epsForward": -1.27, "epsCurrentYear": -0.06, "priceEpsCurrentYear": -32.333336, "longName": "NRx Pharmaceuticals, Inc.", "regularMarketChangePercent": -5.3658485, "regularMarketPrice": 1.94, "displayName": "NRx Pharmaceuticals", "trailingPegRatio": null}